NewAmsterdam Pharma Company N.V. Ordinary Shares - NAMS STOCK NEWS

NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients, has announced the approval of inducement share options. The Compensation Committee granted options for 97,600 ordinary shares to two non-executive new hires at an exercise price of $17.82 per share. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments. These grants were made under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

NewAmsterdam Pharma (Nasdaq: NAMS) has announced its participation in two major conferences this November. The company will present new safety and efficacy data from their Phase 3 BROOKLYN study of obicetrapib at the 2024 American Heart Association Scientific Sessions in Chicago (November 16-18). The study focuses on patients with Heterozygous Familial Hypercholesterolemia.

Additionally, the company's management will participate in the Jefferies London Healthcare Conference (November 19-21). Dr. Stephen Nicholls will present the BROOKLYN study findings on November 18, while CEO Michael Davidson, CSO John Kastelein, and CFO Ian Somaiya will lead a fireside chat on November 21. A live webcast of the Jefferies presentation will be available on the company's investor relations website.

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C, has announced the approval of inducement share options. The Compensation Committee of NewAmsterdam's Board of Directors granted options covering 100,000 ordinary shares to one non-executive new hire.

The share options, granted under the 2024 Inducement Plan, have an exercise price of $17.29 per share, equal to the closing market price on October 1, 2024. The shares will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 equal monthly installments, subject to continued service. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4).

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company, has announced the approval of inducement share options for three new non-executive hires. The Compensation Committee of NewAmsterdam's Board of Directors granted options covering 111,000 ordinary shares under the 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price of $15.91 per share, matching the closing market price on September 3, 2024. The vesting schedule spans four years, with 25% vesting after one year and the remainder vesting in 36 equal monthly installments, contingent on continued employment. These grants are part of NewAmsterdam's strategy to attract talent in its mission to develop oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.

NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin treatments for cardiovascular disease (CVD) patients with high LDL-C, announced its participation in upcoming investor conferences in September.

Management will attend the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 5-6, 2024. CFO Ian Somaiya will meet 1x1 with investors on September 5th and participate in a fireside chat on September 6th at 10:00 a.m. ET.

The company will also be present at the Cantor Global Healthcare Conference in New York City on September 17, 2024. CEO Michael Davidson, M.D., and CFO Ian Somaiya will participate in a fireside chat at 3:40 p.m. ET.

Live webcasts of both events will be available on the NewAmsterdam Pharma investor relations page, with replays accessible afterward.

NewAmsterdam Pharma reported positive topline data from its Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH, achieving the primary endpoint of LDL-C reduction. The company extended US IP protection for obicetrapib into 2043 with a new composition of matter patent. Enrollment for the Phase 3 TANDEM trial evaluating a fixed-dose combination of obicetrapib and ezetimibe was completed, with topline data expected in Q1 2025. NewAmsterdam maintains a strong financial position with $430.7 million in cash. The company reported Q2 2024 financial results, including revenue of $2.3 million, R&D expenses of $38.4 million, and a net loss of $39.0 million. Upcoming milestones include topline data from the Phase 3 BROADWAY trial in Q4 2024.

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced the grant of inducement share options to a new non-executive hire. The Compensation Committee approved options for 59,200 ordinary shares under the 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $17.25 per share, matching the closing market price on August 1, 2024. The shares will vest over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments, subject to continued employment. This grant is part of NewAmsterdam's strategy to attract and retain key talent in its mission to develop innovative cardiovascular treatments.

Menarini Group announces positive topline data from the Phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH). The trial met its primary endpoint, achieving a 36.3% reduction in LDL-C at week 12 and 41.5% reduction at week 52 compared to placebo (p<0.0001). Over 50% of patients achieved LDL-C levels below 70 mg/dl. Obicetrapib was well-tolerated with no increase in blood pressure and fewer treatment-related adverse events than placebo. The BROOKLYN trial is part of obicetrapib's global Phase 3 program, which includes four studies with over 12,250 patients. These results suggest obicetrapib could be a new, high-efficacy, oral option for difficult-to-treat HeFH patients.

NewAmsterdam Pharma (Nasdaq: NAMS) announced positive topline data from its Phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH). The trial met its primary endpoint, achieving a 36.3% reduction in LDL-C compared to placebo at day 84 (p<0.0001), which was sustained at 41.5% reduction at day 365 (p<0.0001). Obicetrapib was observed to be well-tolerated with safety results comparable to placebo and no increase in blood pressure. The treatment discontinuation rate for obicetrapib was 7.6% versus 14.4% for placebo. The trial involved 354 patients randomized 2:1 to receive 10 mg obicetrapib or placebo once daily. These results support obicetrapib's potential to significantly reduce LDL-C in a challenging patient population over one year.